Placebo News and Research

RSS

Study investigates biology of emotional sharing

Therapists have long known that people who've had a traumatic experience feel the need to talk about what they've been through. This process is called 'social sharing' and can take place for days, weeks, months or years after the event.

19 Dec 2012

HAL Allergy completes enrollment in SUBLIVAC FIX Phleum pratense Phase II trial

HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC FIX Phleum pratense.

19 Dec 2012

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon (Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal disease.

18 Dec 2012

Abiraterone improves outcomes for prostate cancer prior to chemo

Treatment with abiraterone acetate, an androgen biosynthesis inhibitor, may benefit patients with progressive metastatic castration-resistant prostate cancer who have not yet undergone chemotherapy, report researchers.

17 Dec 2012

Lapatinib benefits found for HER2-positive early-stage patients

Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology.

17 Dec 2012

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received "Fast Track" status from the U.S. Food and Drug Administration for the development of LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).

17 Dec 2012

GTx achieves enrollment goal for pivotal Phase III clinical studies of enobosarm

GTx, Inc. today announced that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer patients.

17 Dec 2012

IRB Barcelona, BBVA Foundation organize international conference on biostatistics

Statistics have entered the life sciences and they are here to stay. This science emerged in the XVIII century by the hand of the mathematicians Thomas Bayes and Pierre Simon Laplace and was used by Gregor Mendel to demonstrate his theory on genetic inheritance. Since the 90s with the appearance of large genomic studies, statistics has become a fundamental tool for the analysis and interpretation of biomedical data.

16 Dec 2012

Everolimus therapy might treat Myc-driven lymphoma

Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.

15 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

15 Dec 2012

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

14 Dec 2012

High-dose vitamin D can reduce risk of respiratory tract infections

Treating infection-prone patients over a 12-month period with high doses of vitamin D reduces their risk of developing respiratory tract infection - and consequently their antibiotic requirement. This according to a new study by researchers at Karolinska Institutet and Karolinska University Hospital published in the online scientific journal BMJ Open.

14 Dec 2012

Combination therapy reduces sleep apnea symptoms at altitude

Patients with obstructive sleep apnea can better control their symptoms when traveling to higher altitudes by combining autoadjusted continuous positive airway pressure with acetazolamide, research suggests.

14 Dec 2012

ETA receptor antagonism reduces novel cardiovascular risk factors in patients with CKD

Blocking the receptor for proteins that constrict blood vessels reduces markers of heart-related problems in patients with chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

14 Dec 2012

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the publication of data from its first-in-human Phase 1 study of its NDV-3 vaccine program in the journal Vaccine.

13 Dec 2012

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

13 Dec 2012

Fingolimod associated with modest, rapid increase in macular volume

Patients with multiple sclerosis treated with fingolimod undergo a modest but rapid increase in macular volume, research shows.

13 Dec 2012

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Eli Lilly and Company today provided an update on the next steps planned for solanezumab, its Phase 3 monoclonal antibody being studied as a potential therapy for patients with mild Alzheimer's disease.

13 Dec 2012

Bumetanide could treat children with severe autism or Asperger's syndrome

Although this therapy is not curative, it nevertheless reduced the autistic disorders' severity in three-quarters of the children. The researchers have filed a request for authorisation to perform a multi-centre European clinical trial in order to determine more precisely the population concerned by this therapy.

13 Dec 2012

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

13 Dec 2012

Placebo News and Research

Study investigates biology of emotional sharing

HAL Allergy completes enrollment in SUBLIVAC FIX Phleum pratense Phase II trial

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

Abiraterone improves outcomes for prostate cancer prior to chemo

Lapatinib benefits found for HER2-positive early-stage patients

Lexicon receives FDA Fast Track status for development of LX1033 for irritable bowel syndrome

GTx achieves enrollment goal for pivotal Phase III clinical studies of enobosarm

IRB Barcelona, BBVA Foundation organize international conference on biostatistics

Everolimus therapy might treat Myc-driven lymphoma

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

High-dose vitamin D can reduce risk of respiratory tract infections

Combination therapy reduces sleep apnea symptoms at altitude

ETA receptor antagonism reduces novel cardiovascular risk factors in patients with CKD

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

Fingolimod associated with modest, rapid increase in macular volume

Eli Lilly provides update on solanezumab Phase 3 clinical study for mild Alzheimer's

Bumetanide could treat children with severe autism or Asperger's syndrome

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News